Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays

Donata Santarsiero; Sara Gastoldi; Valeria Guaschino; Elena Bresin; I Pagani; Andrea Pasini; Elena Romano; Ariela Benigni; Giuseppe Remuzzi; Marina Noris; Sistiana Aiello

doi:10.1016/j.ekir.2025.103717

Related publications

Article2013

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Christophe Legendre, Christoph Licht, Petra Muus, Larry A. Greenbaum, Sunil Babu, Camille L. Bedrosian, Coralie Bingham, D.J. Cohen, Yahsou Delmas, K. Douglas, Frank Eitner, Thorsten Feldkamp, Denis Fouque, Richard R. Furman, Osama Gaber, Maria Herthelius, Maryvonne Hourmant, Diana Karpman, Yvon Lebranchu, Christophe Mariat, Jan Menne, Bruno Moulin, Jens Nürnberger, Masayo Ogawa, Giuseppe Remuzzi, Tristan Richard, Rébecca Sberro‐Soussan, Beth Severino, N. Sheerin, Antonella Trivelli, Lothar Bernd Zimmerhackl, Tim Goodship, Chantal Loirat

Article2009

C5a/C5aR interaction mediates complement activation and thrombosis on endothelial cells in atypical hemolytic uremic syndrome (aHUS)

Sara Gastoldi, Marina Noris, Paolo Macor, Francesco Tedesco, Federica Banterla, Elena Bresin, Roberta Donadelli, Giuseppe Remuzzi, Miriam Galbusera

Complement Alternative Pathway Dominance in Atypical Hemolytic Uremic Syndrome Revealed by Endothelial Bioassays

Discussion(0)

Related publications

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Atypical Hemolytic–Uremic Syndrome

Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype

Screening for Complement System Abnormalities in Patients with Atypical Hemolytic Uremic Syndrome

C5a/C5aR interaction mediates complement activation and thrombosis on endothelial cells in atypical hemolytic uremic syndrome (aHUS)